Resective surgery to treat refractory status epilepticus in children with focal epileptogenesis

Resective surgery to treat refractory status epilepticus in children with focal epileptogenesis

Prolonged high-dose suppressive therapy (HDST) is a mainstay in the management of refractory status epilepticus (RSE), albeit with high morbidity and mortality. The authors studied 10 patients who were carefully selected for epilepsy surgery after failing prolonged (>2 weeks) HDST. Status epilept...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2005-02, Vol.64 (3), p.567-570
Hauptverfasser: ALEXOPOULOS, A, LACHHWANI, D. K, GUPTA, A, KOTAGAL, P, HARRISON, A. M, BINGAMAN, W, WYLLIE, E
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Anticonvulsants - therapeutic use
Biological and medical sciences
Brain - abnormalities
Child
Combined Modality Therapy
Encephalitis - complications
Epilepsies, Partial - drug therapy
Epilepsies, Partial - etiology
Epilepsies, Partial - surgery
Female
Follow-Up Studies
Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy
Hemianopsia - epidemiology
Hemispherectomy
Humans
Infant
Infarction, Middle Cerebral Artery - complications
Male
Medical sciences
Nervous system (semeiology, syndromes)
Nervous system as a whole
Neurology
Paresis - etiology
Postoperative Complications
Retrospective Studies
Status Epilepticus - etiology
Status Epilepticus - surgery
Treatment Outcome
Tuberous Sclerosis - complications
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Prolonged high-dose suppressive therapy (HDST) is a mainstay in the management of refractory status epilepticus (RSE), albeit with high morbidity and mortality. The authors studied 10 patients who were carefully selected for epilepsy surgery after failing prolonged (>2 weeks) HDST. Status epilepticus was stopped acutely in all of them with no mortality and no substantial morbidity. At follow-up (median 7 months), 7 (70%) of 10 patients were seizure free, and 3 (30%) of 10 had significant improvement in their epilepsy.
ISSN:0028-3878
1526-632X
DOI:10.1212/01.WNL.0000150580.40019.63